EMPE Diagnostics, founded in 2015 and rooted in innovations from the Karolinska Institute, develops rapid, reliable, and cost-effective diagnostic solutions to address the global tuberculosis (TB) crisis. Its CDSCO–approved product, mfloDx™ MDR-TB, is manufactured at an ISO 13485–certified facility in Hyderabad, India and enables the detection of Mycobacterium tuberculosis along with key drug-resistance mutations. EMPE Diagnostics continues to expand its portfolio with the recently launched EMPE TBDx, a Research Use Only (RUO) qPCR assay for rapid and accurate detection of Mycobacterium tuberculosis complex (MTBC) from pulmonary samples.
